Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_02135 |
| Species: | Mus musculus |
| Position : | chr1:179953600-179954900 |
| Year: | 2024 |
| Title: | A conserved ACTN2 enhancer regulates cardiomyocyte maturation through mTOR signaling |
| Genome Build: | mm10 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| Disease Name: | -- |
| PMID: | 38824572 |
| MONDO: | |
| Tissue: | Heart |
| Tissue Ontology ID: | UBERON:0000948 |
| Cell Source: | Mouse primary cardiomyocytes |
| CVCL ID: | |
| Cell Type: | mouse cardiomyocyte |
| Cell Ontology ID: | CL:0000746 |
| Experiment Type: | Enhancer activity assay, TF binding assay |
| High Throughput Method: | RNA-seq, ChIP-seq, ATAC-seq |
| Low Throughput Method: | CRISPR Knockout, ChIP-RT-qPCR, RT-RT-qPCR, Western blot |
| Target gene : | Actn2 |
| TF name : | Mef2A |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| Mef2A | CDO in myogenesis | reactome | 29 |
| Mef2A | ERK/MAPK targets | reactome | 17 |
| Mef2A | Signaling mediated by p38-alpha and p38-beta | pid | 35 |
| Mef2A | TGF_beta_Receptor | netpath | 220 |
| Mef2A | Hs_p38_MAPK_Signaling_Pathway_WP400_72084 | wikipathways | 28 |